University of California, Los Angeles School of Public Health, Los Angeles, CA, USA.
Vaccine. 2011 Dec 30;29 Suppl 4(Suppl 4):D60-4. doi: 10.1016/j.vaccine.2011.09.004. Epub 2011 Dec 19.
Monkeypox (MPX) is a virulent orthopoxvirus that is endemic in some regions of Central Africa. MPX incidence has been rising since the cessation of routine smallpox immunization. While it causes significant disease, there is limited person-to-person spread, the incidence is still relatively low, and cases are generally restricted to remote areas that are difficult to access. Therefore, initiating vaccine trials or implementing vaccination programs would be challenging. This paper considers the factors that may influence future decisions on whether MPX vaccination should be pursued.
猴痘(MPX)是一种烈性正痘病毒,在中非的一些地区流行。自常规天花免疫停止以来,MPX 的发病率一直在上升。虽然它会导致严重的疾病,但人与人之间的传播有限,发病率仍然相对较低,而且病例通常限于难以到达的偏远地区。因此,启动疫苗试验或实施疫苗接种计划将具有挑战性。本文考虑了可能影响未来是否进行 MPX 疫苗接种决策的因素。